I looked at your last 20 posts and they are all the same. Guess this your way of feeling powerful, being abusive on anonymous boards. Based on your posts you have have a couple of thousand dollars worth of SPHS shares and you stoop to this. What a wasted life.
SPH has spewed all it had and it is an abject failure. The company will go bankrupt shortly but not until serial dilutions have bankrupted all the ostriches with their heads in the sand who still tout the company but are terrified inside. It takes a particularly stupid individual to come an brag about a failing competitor on the NYMX Board. For the sake of humanity please don't have children.
To be honest,I do not think the shares are a big issue for him. He owns enough of the company to make them meaningless in a relative sense. He is no spring chicken and I think is in a hurry, wants his cash and glory now.
We are all nervous and jittery and the increasing volume to the downside suggests some investors are bailing. I am no fan of Warren Buffet but agree with him when he said something to the effect that the stock market is a mechanism for transferring money from the impatient to the patient.
GL to us all.
I did not say a trial is going on I said discussion about the trial and when they announce a trial they will obviously announce an agreement and funding through BP.
My mistake about the Feb announcement, you are right it refers to the Recordati trail which is now over. The rest about looking at the BPH results in April still stands and is from a more recent update as below.
Jul 15: Nymox announces that an extension of two PIII have produced positive results. After 3.5 years, there were positive long-term improvements in symptoms of BPH, fewer BPH surgeries and a good safety profile. Nymox announced plans to take a look at the post-12-month data in April. Additional new blinded protocol data from the same pivotal studies was prospectively captured in order to assess long-term results in patients up to 5 years after a single injection of NX-1207 2.5 mg vs placebo .
Still implies to my mind further news out shortly.
I have made no secret of my belief that they will need a small EU trial for BPH both for EU approval and to increase their chances of FDA approval. I ran a search for new trials and this is what I came up with
Jul 15: Nymox now intends to meet with authorities with extension data and to proceed to file where possible in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories .
... approvals for fexapotide triflutate in various jurisdictions and territories . .... Feb 12: A European PIII trial is to start following discussions with the EMA. ... and no current drug treatment for their BPH and had an ongoing mean improvement ...
Ukmi nhs uk. This is the source of the information.
Suggests that there are ongoing discussions for an UK trial and as some other poster reported recently additional data on the BPH trials is coming soon.
Show me the line where it states the higher dose ablated the tumours and the non responders received the lower dose. The question was asked at the end but they detoured to higher doses per cancer. Don't believe me, ask SPHS or your gambler friend.
I state facts, they were right before and should be right now. If they are wrong prove it and I will be more than willing to admit to my error.
Wrong? I called it before the rise and the SP crashed back to where it was trading before the hype as it will now. As for NYMX it is still trading at a price of six times where it was after the crash. Crawl back to your slimy hole and be tough on another anonymous message board.
I think you are going to be sandbagged in your position in SPHS. Your information is andinacurate and misleading. I guess you are a SPHS pumper in disguise.
I dont think so. I did not reply before because I wanted to listen to the SPHS call.
First they injected one lesion using a special MRI (parametric) among multiple as prostate cancer is multifocal. Secondly nowhere in the entire call did they say there was a relationship between the dose injected and tumour response or the non responders got lower doses. The dose part is 10-13 and 21-22 minutes in the call if you want to go back and listen. In fact they said they will try an infusion of the drug which means a hospital admission as they could not figure out the correct dose.
So you need first a parametric MRI a very specialized piece of equipment available only in specialized research hospitals and identify which out of the many lesions you can treat and to treat the lesion you admit the patient to the hospital each time you want to treat it. The drug is a total bust and Randy is a scammer and guess who is getting scammed.
The NYMX drug by the way treated all lesions in the cancer using an ultrasound which is what urologists commonly use and worked in a lot more than 18 patients.
SPHS is flying tonight after releasing its stage 1 excuse me stage 2A prostate cancer study in which 18 patients had their drug injected into early localized prostate cancer using a very special MRI. Results of 18 patients 9 had no response and 2 had complete resolution of their early stage prostate cancer and 7 showed some effect.
Hormone sensitive breast and prostate cancer in early cancer shows a 20-25% spontaneous regression rate. The results to me are good evidence that the drug does not work in prostate cancer but SPHS is spinning it the other way with our very own JC Smith cheerleading them. Proving two things. There is a sucker borne every minute and great short opportunity setting up in SPHS.
Volume is improved. Chirping birds who claim to be in the know are silent. All hopeful signs.